1. Home
  2. UCTT vs MLYS Comparison

UCTT vs MLYS Comparison

Compare UCTT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UCTT
  • MLYS
  • Stock Information
  • Founded
  • UCTT 1991
  • MLYS 2019
  • Country
  • UCTT United States
  • MLYS United States
  • Employees
  • UCTT N/A
  • MLYS N/A
  • Industry
  • UCTT Semiconductors
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • UCTT Technology
  • MLYS Health Care
  • Exchange
  • UCTT Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • UCTT 1.1B
  • MLYS 890.6M
  • IPO Year
  • UCTT 2004
  • MLYS 2023
  • Fundamental
  • Price
  • UCTT $22.11
  • MLYS $13.19
  • Analyst Decision
  • UCTT Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • UCTT 3
  • MLYS 4
  • Target Price
  • UCTT $39.00
  • MLYS $27.00
  • AVG Volume (30 Days)
  • UCTT 518.4K
  • MLYS 679.2K
  • Earning Date
  • UCTT 07-28-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • UCTT N/A
  • MLYS N/A
  • EPS Growth
  • UCTT N/A
  • MLYS N/A
  • EPS
  • UCTT N/A
  • MLYS N/A
  • Revenue
  • UCTT $2,141,100,000.00
  • MLYS N/A
  • Revenue This Year
  • UCTT N/A
  • MLYS N/A
  • Revenue Next Year
  • UCTT $1.85
  • MLYS N/A
  • P/E Ratio
  • UCTT N/A
  • MLYS N/A
  • Revenue Growth
  • UCTT 14.28
  • MLYS N/A
  • 52 Week Low
  • UCTT $16.66
  • MLYS $8.24
  • 52 Week High
  • UCTT $41.90
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • UCTT 43.63
  • MLYS 43.58
  • Support Level
  • UCTT $21.60
  • MLYS $12.70
  • Resistance Level
  • UCTT $23.35
  • MLYS $13.70
  • Average True Range (ATR)
  • UCTT 1.23
  • MLYS 0.73
  • MACD
  • UCTT -0.26
  • MLYS -0.07
  • Stochastic Oscillator
  • UCTT 13.20
  • MLYS 20.00

About UCTT Ultra Clean Holdings Inc.

Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: